Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC 3Q11 Trend Analysis, now available
    - OnBioVC 4Q11 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • FDA Registered Contract Manufacturer

Ember Therapeutics (Boston, MA) a preclinical-stage pharmaceutical company focused on diabetes, obesity and metabolic diseases closed a $34.1M Series A financing. Participants include Third Rock Ventures.

Aviir (Irvine, CA) a commercial-stage diagnostic company focused on pharmacogenomic and genetic tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders, closed a $10M Series E financing. Participants include Merck Global Health Innovation, Bay City Capital, Aberdare Ventures and New Leaf Venture Partners.

Agios Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on cancer metabolism, closed a $78M Series C financing. Participants have included Celgene, ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Ultragenyx Pharmaceutical (Novato, CA) a clinical-stage pharmaceutical company focused on inclusion body myopathy and other rare metabolic disease,vclosed a $45M Series A financing. Participants include TPG Biotech, Fidelity Biosciences, HealthCap and Pappas Ventures.

Nimbus Discovery (Cambridge, MA) a development-stage biopharmaceutical focused on computational technologies to identify lead candidates for diffuse B-cell lymphoma and metabolic disease, closed a $1.5M Series A bringing the total financing to $5M. Participants include the Bill and Melinda Gates Foundation and Atlas Venture.

Synageva BioPharma (Lexington, MA) a clinical-stage biopharma focused on rare diseases and orphan therapeutics for the treatment of lysosomal storage disease and metabolic disorders, closed a $25M Series C financing. Participants have included New Leaf Venture Partners, Hunt BioVentures, Yasuda Enterprise Development, Baker Brothers Investments, Tullis Dickerson and Four Partners.

Acylin Therapeutics (Seattle, WA) a development-stage biopharma company focused on inhibiting histone acetyltransferase in cancer, metabolic disease, and neurodegeneration indications, closed a $4.4M Series F financing. Participants include Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD and Washington Research Foundation Capital.

aTyr Pharma (San Diego, CA) a preclinical-stage biopharmaceutical company focused on immune, metabolic and hematologic indications, closed a $23M Series C financing. Participants include Domain Associates, Alta Partners, Cardinal Partners and Polaris Ventures.

NewBridge Pharmaceuticals (San Francisco, CA) a commercial-stage biopharmaceutical company focused on oncology, GI and metabolic disorders, closed a $12M Series B financing. Participants include Kuwait Life Sciences Company and Burrill & Co.

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Aquinox Pharmaceuticals (Canada) a preclinical-stage small-molecule drug company focused on cancer, immune disorders and metabolic disease, closed a $25M Series B financing. Participants include Ventures West Capital, Johnson & Johnson Development Corp., Baker Brothers Investments, BC Advantage Funds and Pfizer Venture Investments.

Catabasis Pharmaceuticals (Cambridge, MA) a preclinical-stage company focused on lipid mediators for the treatment of inflammatory and metabolic diseases, closed a $39.6M Series A financing. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

NGM Biopharmaceuticals (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on diabetes, obesity and muscle wasting, closed a $51M Series B financing. Participants include The Column Group, Tichenor Ventures, Prospect Venture Partners and Rho Ventures.

« Previous Entries  

to top of page...